In This Article:
Amgen's recent affirmation of a $2.38 per share dividend for Q2 2025 could reflect investor confidence and perhaps aided in boosting its shares by 12% over the last quarter. The company's financial performance, highlighted by a revenue increase for 2024 despite a decrease in net income, indicates resilience. Concurrently, their product developments, such as the positive Phase III results for TEZSPIRE® and FDA approval for LUMAKRAS®, signal strong therapeutic advancements. The announcement of Amgen’s $1 billion expansion in North Carolina and their pursuit of acquisitions underscore their growth ambitions. While broader market conditions saw volatility, Amgen's strategic progress and shareholder returns appear to resonate with investors. As the market wavered amid tariff uncertainties and mixed economic signals, Amgen's focus on robust dividends and corporate growth initiatives likely played a key role in driving their stock performance.
Navigate through the intricacies of Amgen with our comprehensive report here.
Over the last five years, Amgen's shares delivered a total return of 76.03%, reflecting a solid performance amid various industry challenges. Notably, Amgen's recent Horizon Therapeutics acquisition, announced in 2024, and their continued investment like the US$1 billion expansion in North Carolina, have showcased their commitment to growth and innovation. This aligns with robust buyback activities, highlighted by the repurchase of 718,799 shares worth US$200.01 million from October to December 2024, signaling confidence in the company's valuation.
Amgen's FDA approval of LUMAKRAS® in combination with Vectibix in 2025 for treating KRAS G12C-mutated metastatic colorectal cancer and successful Phase III results for TEZSPIRE® further underscore their advancements in therapeutics. Despite a challenging profit landscape, with earnings declining at 9% annually over the past five years, these strategic maneuvers and product approvals have enabled Amgen to outperform the US Biotechs industry, which faced a 7.6% decline over the past year.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.